Agreement to Indemnify Directors or Officers of a Company or its Subsidiaries (US)
This is a sample indemnification agreement under which a company agrees to indemnify the directors and/or officers of the company or its subsidiaries.
This is a sample indemnification agreement under which a company agrees to indemnify the directors and/or officers of the company or its subsidiaries.
This is sample operating agreement between members of a Delaware limited liability company (LLC).
This sample matrix shows levels of decision-making authority per type of decision, agreement or act involved. The matrix distinguishes between decision makers, alternate decision makers, or persons who must be consulted or must be informed.
This is a sample company policy setting out general guidance and dollar limitations to which management and employees may commit the Company, the level(s) of management by which certain categories of commitments must be approved, and general procedures for requesting and obtaining such approval.
This Latham & Watkins article analyzes the proposed rules and advises SEC registrants on how to prepare for compliance with the proposed cyber rules in May of 2022.
This is a sample board resolution approving the repurchase of a company's common stock and authorizing the company's officers to carry out the repurchase, under Delaware law (United States).
This is a sample limited liability company (LLC) operating agreement for the state of Virginia - agreement between the company and the sole member of the LLC.
This is a sample indemnification agreement for the indemnification by a company of its directors and officers, governed by Delaware law.
Canada is an attractive market for pharmaceutical manufacturers. Most Canadian consumers have some form of drug coverage through government programs and/or private insurance. Below are ten patent and regulatory topics that in-house counsel need to know before bringing an innovative product to Canada.
Editor's note: This article was updated to reflect recent developments; the original version of this article was published on December 16, 2020.
The September 2017 amendments to the Patented Medicines (Notice of Compliance) Regulations introduced a new scheme for pharmaceutical patent linkage litigation in Canada. That scheme is now much closer to the United States' (US) Hatch-Waxman scheme, but with remaining key differences that are explained in this chart.